TROP2-Directed Antibody–Drug Conjugates in Non-Small-Cell Lung Cancer: Current Use in Clinical Practice and Future Directions

In this episode, Dr Matthew Gubens and Dr Helena Yu discuss the evolving role of TROP2-directed therapies in non-small-cell lung cancer, with a focus on how antibody–drug conjugates (ADCs) fit into current treatment strategies, including

The mechanism of action and clinical trial outcomes of TROP2-directed ADCs like datopotamab deruxtecan and sacituzumab tirumotecan Use of these therapies in EGFR-mutant disease and how they fit into a changing treatment landscape Practical advice on associated adverse events and additional considerations, A look at future directions on the horizon, such as first-line studies and predictive biomarkers

Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify.

Presenters:

Matthew Gubens, MD, MS, FASCO​
Medical Director, Thoracic Medical Oncology​
University of California, San Francisco​
San Francisco, California

Helena Yu, MD​
Professor of Medicine​
Thoracic Oncology Service​
Memorial Sloan Kettering Cancer Center​
New York, New York

Link to full program:
https://bit.ly/41vAnfH

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.